Pediatric Cancers | Topics

FDA Grants Accelerated Approval to Naxitamab-gqgk Combo for the Treatment of Neuroblastoma
November 30, 2020

The FDA granted accelerated approval to naxitamab-gqgk (Danyelza) in combination with GM-CSF for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.

Radiation May Cause Body Composition Abnormalities in Adult Survivors of Pediatric Cancer
October 01, 2020

A study found that radiation therapy to treat childhood abdominal and pelvic cancers potentially caused body composition abnormalities and worse cardiometabolic health for adult survivors compared to the general public.

Researchers Receive Grant to Initiate Study of ‘Chemo Brain’ in Pediatric Patients
September 02, 2020

This study is intended to “investigate how chemotherapy disrupts sensory processing, memory, and attention in children; where in the brain the damage is occurring; and whether there is a biomarker that can identify those who are most vulnerable.”